Wen-Kuan Huang, Chuang-Chi Liaw, See-Tong Pang, Cheng-Keng Chuang, Yang-Jen Chiang, Chun-Te Wu, Ying-Hsu Chang, Hung-Ming Wang, Yung-Chang Lin, Jia-Juan Hsieh, Li-Ying Ou, Shih-I Tsai, Chih-Hsun Yang, Cheng-Ta Yang, John Wen-Cheng Chang
BACKGROUND: Everolimus has been approved for second-line treatment of patients with metastatic renal cell carcinoma (mRCC) after failure of sorafenib or sunitinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC. METHODS: Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior to everolimus, each patient had received therapy with at least one vascular endothelial growth factor receptor-tyrosine kinase inhibitor...
September 2012: Chang Gung Medical Journal